Tracking
INSIGHTS
Home 9 All Posts 9 Strategy 9 Launching a Specialty Therapy? Don’t Fly Blind.
Sara Schardein
  •  November 09

Launching a Specialty Therapy? Don’t Fly Blind.

Launch a specialty therapy with confidence. Archbow Consulting’s fair market value benchmarking and negotiation guidance help pharma manufacturers assess distribution and service fees.

Launching a Specialty Therapy? Don’t Fly Blind.

A specialty therapy launch is a lot like flying a complex aircraft: success depends on having the right information at the right moment. Yet many manufacturers enter critical distribution and service fee negotiations with limited visibility into what the market considers fair, leaving them to navigate by assumption, precedent, or whatever terms a partner puts on the table first. When the data goes dark, even experienced teams can find themselves recalculating at exactly the wrong time.

Archbow Consulting’s Fair Market Value (FMV) services give pharma manufacturers a clear view of the landscape ahead. We provide benchmark pricing and custom service fee analysis so you can launch with clarity and confidence, not guesswork.

Our FMV benchmarking gives you the instrument panel you need, including current market data, service fee analysis, pricing comparables, and negotiation strategy. Rather than evaluating a single fee in isolation, we look at the full picture: the product’s characteristics, anticipated volume, distribution model, service requirements, operational complexity, and the data and reporting expectations assigned to each partner. This context matters, because a fee that looks reasonable on its own may not be aligned with the services, risk, and performance expectations behind it.

Archbow also acts as your co-pilot when it is time to put the data to work. Drawing on deep expertise in pharmaceutical commercialization, specialty distribution, dispensing, market access, and supply chain operations, we translate benchmark insights and partner fee requests into actionable guidance for negotiations. We help you define a well-supported target position, evaluate contract terms and service-level expectations, and prepare for productive discussions with your partners, so you are not charting your course alone.

These services are especially valuable for manufacturers preparing to bring a specialty therapy to market, when early decisions about distribution and service fees set the tone for the commercial relationship. Entering those conversations with defensible benchmarks and a clear negotiation strategy can help you move forward with greater confidence and avoid costly course corrections after takeoff.

Your launch is too important to navigate without visibility. Contact Archbow Consulting to talk about how our FMV services can help you see the whole picture and launch with clarity and confidence.

For additional insights on this topic, you may also enjoy the following:

Archbow Consulting helps pharmaceutical and biotech companies in the USA and Europe design, build, and optimize product distribution and patient access strategies. Archbow was founded by industry veterans to meet a need in the marketplace for consulting options that offer diverse real-world experience, are able to leverage deep connections across the industry, and can also provide actionable strategic guidance. We invite you to learn more about our team, services, and clients’ success, and connect with us via email, LinkedIn or subscribing to this blog which you can do below.
Share in
Recent Posts
Preparing for the FDA’s 12-Digit NDC Transition

Preparing for the FDA’s 12-Digit NDC Transition

Manufacturers should begin planning early to assess impacts, align stakeholders, update affected processes, and allow sufficient time for testing and implementation before the March 7, 2033 deadline.

SUBSCRIBE

Subscribe to receive news and updates from Archbow Consulting

Tracking